Information Provided By:
Fly News Breaks for February 14, 2018
DVAX
Feb 14, 2018 | 06:54 EDT
JPMorgan analyst Anupam Rama downgraded Dynavax to Neutral and lowered his price target for the shares to $25 from $31. The analyst believes 2018 appears to be more of a market prep year for the company with 2019 an inflection year. He is not expecting Heplisav to be a key upside driver for shares this year and thinks Dynavax's pipeline needs further de-risking.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.